Kazia Therapeutics Limited
KZIA
$13.16
-$0.67-4.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -98.22% | -98.26% | -- |
| Total Other Revenue | 313.70% | 301.33% | 891.58% | 872.76% | -- |
| Total Revenue | 313.70% | 301.33% | -29.21% | -30.53% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 313.70% | 301.33% | -29.21% | -30.53% | -- |
| SG&A Expenses | 68.73% | 63.58% | -61.03% | -61.76% | 12.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.34% | 40.90% | -70.67% | -71.22% | 5.70% |
| Operating Income | -44.69% | -40.27% | 75.93% | 76.38% | -5.45% |
| Income Before Tax | -19.40% | -15.75% | 36.28% | 37.47% | -18.18% |
| Income Tax Expenses | -- | -- | -1,056.50% | -1,035.06% | 0.00% |
| Earnings from Continuing Operations | -20.95% | -17.25% | 44.51% | 45.55% | -18.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.95% | -17.25% | 44.51% | 45.55% | -18.46% |
| EBIT | -44.69% | -40.27% | 75.93% | 76.38% | -5.45% |
| EBITDA | -55.16% | -50.41% | 77.15% | 78.38% | -6.09% |
| EPS Basic | 67.04% | 68.05% | 76.21% | 76.66% | 33.19% |
| Normalized Basic EPS | 69.62% | 70.54% | 88.02% | 88.24% | 27.27% |
| EPS Diluted | 67.03% | 68.03% | 76.21% | 76.66% | 33.19% |
| Normalized Diluted EPS | 69.62% | 70.54% | 88.02% | 88.24% | 27.27% |
| Average Basic Shares Outstanding | 266.98% | 266.98% | 133.25% | 133.25% | 77.29% |
| Average Diluted Shares Outstanding | 264.71% | 264.71% | 136.36% | 136.36% | 88.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |